Company Description
Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases.
Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa; and RPIDD, a liquid biopsy rapid pathogen diagnostic which is in preclinical trial to treat pathogen molecular diagnostics.
The company also develops SACT-COV19, a repurposed small molecule which is in preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule which is in preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule which is in preclinical trial for the treatment of gram+ve bacterial infections.
In addition, it is developing NLS-1, which is in preclinical trial for the treatment of endometriosis; DLS-1+2, which is in preclinical trial to treat NSCLC with mutation; DLS-3, which is in preclinical trial to treat autoimmune disease; CLS-1, a macromolecule, which is in preclinical trial to treat obesity; and CLS-1 and CLS-3.
Further, the company offers NativusWell DOI (NLS-2), a dietary supplement for women undergoing menopause; and provides management services.
The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017.
Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.
| Country | United Kingdom |
| Founded | 2010 |
| IPO Date | Dec 18, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1 |
| CEO | Chung Yuen Huen |
Contact Details
Address: 17 Hanover Square London, W1S 1BN United Kingdom | |
| Phone | 44 20 8092 9299 |
| Website | aptorumgroup.com |
Stock Details
| Ticker Symbol | APM |
| Exchange | NASDAQ |
| Share Class | Class A Shares |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001734005 |
| CUSIP Number | G6096M106 |
| ISIN Number | KYG6096M1226 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Chung Yuen Huen | Founder, Chief Executive Officer and Executive Director |
| Kwok Kuen Wong | Head of Finance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 15, 2025 | SCHEDULE 13G/A | Filing |
| Apr 30, 2025 | 20-F | Annual and transition report of foreign private issuers |
| Apr 16, 2025 | 6-K | Report of foreign issuer |
| Jan 10, 2025 | SCHEDULE 13G | Filing |
| Jan 7, 2025 | 6-K | Report of foreign issuer |
| Jan 6, 2025 | SCHEDULE 13G | Filing |
| Jan 3, 2025 | 424B5 | Filing |
| Dec 20, 2024 | 6-K | Report of foreign issuer |
| Dec 11, 2024 | 6-K | Report of foreign issuer |
| Nov 8, 2024 | 6-K | Report of foreign issuer |